Market closed
Xenon Pharmaceuticals/XENE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Ticker
XENE
Sector
Trading on
Industry
Biotechnology
Headquarters
Burnaby, Canada
Employees
255
Website
XENE Metrics
BasicAdvanced
$3.2B
Market cap
-
P/E ratio
-$2.73
EPS
1.25
Beta
-
Dividend rate
Price and volume
Market cap
$3.2B
Beta
1.25
52-week high
$50.99
52-week low
$27.99
Average daily volume
350K
Financial strength
Current ratio
23.273
Quick ratio
23.091
Long term debt to equity
1.028
Total debt to equity
1.189
Management effectiveness
Return on assets (TTM)
-18.92%
Return on equity (TTM)
-26.71%
Valuation
Price to book
3.75
Price to tangible book (TTM)
3.75
Price to free cash flow (TTM)
-19.466
Growth
Earnings per share change (TTM)
9.12%
3-year earnings per share growth (CAGR)
24.95%
What the Analysts think about XENE
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Xenon Pharmaceuticals stock.
XENE Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
XENE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
XENE News
AllArticlesVideos
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
GlobeNewsWire·3 weeks ago
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
GlobeNewsWire·2 months ago
Polarean Imaging appoints Xenon MRI specialist as its chief medical advisor
Proactive Investors·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Xenon Pharmaceuticals stock?
Xenon Pharmaceuticals (XENE) has a market cap of $3.2B as of October 26, 2024.
What is the P/E ratio for Xenon Pharmaceuticals stock?
The price to earnings (P/E) ratio for Xenon Pharmaceuticals (XENE) stock is 0 as of October 26, 2024.
Does Xenon Pharmaceuticals stock pay dividends?
No, Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next Xenon Pharmaceuticals dividend payment date?
Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders.
What is the beta indicator for Xenon Pharmaceuticals?
Xenon Pharmaceuticals (XENE) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.